The giant blood plasma processing company Grifols on Monday said it has agreed to buy Alkahest, a Silicon Valley startup founded by Genentech alums that’s betting that proteins in plasma can fight diseases including Alzheimer’s and Parkinson’s.
The planned acquisition is primed to bring new resources and recognition to the quixotic, often controversial search for an elixir for diseases associated with aging.
About the Author Reprints
